Breakpoints cover image

#68 – IDWeek 2022 Recap: Late Breaking Trials and Pipeline Antibacterials

Breakpoints

00:00

Cepheum Tannibor Bactam

Cepheum tannibor bactam, which was developed by Venetatorex. This agent is currently in phase 2 studies looking again at that treatment refactory MAC disease of the lung. It's a bicyclic boronate beta lactamase inhibitor. And so what does that mean? It means it inhibits serine and metallobatal actamases. So they're going to pursue NDA submission 2023 and we'll also start a HAP VAP trial for that.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app